Notogen is a biotechnology company dedicated to addressing back and neck dysfunction resulting from spinal disc degeneration. Their primary product, NTG-101, is a patented, protein-based, non-cellular injectable treatment designed to protect spinal discs from degeneration, promote disc regeneration, and alleviate discogenic pain. This innovative approach offers a non-surgical alternative to traditional treatments, minimizing the risks associated with invasive procedures and cell therapies. The development of NTG-101 is supported by clearly defined regulatory and manufacturing pathways, allowing for scalability in production and a streamlined process toward clinical trials.

The scientific foundation of Notogen's technology is rooted in extensive research, particularly the work of their Chief Scientific Officer, Dr. Mark Erwin, who has published numerous studies in peer-reviewed journals. These publications highlight the therapeutic potential of notochordal cells and their secreted factors in promoting the health and regeneration of intervertebral discs. Notogen's approach leverages the biological properties of these cells to develop effective treatments for degenerative disc disease, positioning the company at the forefront of regenerative medicine in spinal health.

Canada

Notogen is developing a novel biologic regenerative therapy to treat degenerative disc disease (i.e. chronic back and neck pain as a result of degenerating spinal discs). The product, which is pre-clinical and currently undergoing cGMP manufacturing, is an injectable solution that is fast to administer, cost-effecti ... see more

Notogen

Company Details